Готові списки джерел за темами / Proteomics, fatty acids, cardiovascular disease

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "Proteomics, fatty acids, cardiovascular disease"

Автор: Grafiati
Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Proteomics, fatty acids, cardiovascular disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Proteomics, fatty acids, cardiovascular disease"

1

Zhang, Yang, Ao Zhang, Laidi Wang, Ting Yang, Bingqiang Dong, Zhixiu Wang, Yulin Bi, Guohong Chen, and Guobin Chang. "Metabolomics and Proteomics Characterizing Hepatic Reactions to Dietary Linseed Oil in Duck." International Journal of Molecular Sciences 23, no. 24 (December 10, 2022): 15690. http://dx.doi.org/10.3390/ijms232415690.

Повний текст джерела
Анотація:
The imbalance in polyunsaturated fatty acid (PUFA) composition in human food is ubiquitous and closely related to obesity and cardiovascular diseases. The development of n-3 PUFA-enriched poultry products is of great significance for optimizing fatty acid composition. This study aimed to improve our understanding of the effects of dietary linseed oil on hepatic metabolism using untargeted metabolomics and 4D label-free proteome analysis. A total of 91 metabolites and 63 proteins showed differences in abundance in duck livers between the high linseed oil and control groups. Pathway analysis revealed that the biosynthesis of unsaturated fatty acids, linoleic acid, glycerophospholipid, and pyrimidine metabolisms were significantly enriched in ducks fed with linseed oil. Meanwhile, dietary linseed oil changed liver fatty acid composition, which was reflected in the increase in the abundance of downstream metabolites, such as α-linolenic acid (ALA; 18:3n-3) as a substrate, including n-3 PUFA and its related glycerophospholipids, and a decrease in downstream n-6 PUFA synthesis using linoleic acid (LA; 18:2n-6) as a substrate. Moreover, the anabolism of PUFA in duck livers showed substrate-dependent effects, and the expression of related proteins in the process of fatty acid anabolism, such as FADS2, LPIN2, and PLA2G4A, were significantly regulated by linseed oil. Collectively, our work highlights the ALA substrate dependence during n-3 PUFA synthesis in duck livers. The present study expands our knowledge of the process products of PUFA metabolism and provides some potential biomarkers for liver health.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Wu, Ping-Hsun, Yi-Wen Chiu, Hsin-Bai Zou, Cheng-Chih Hsu, Su-Chu Lee, Yi-Ting Lin, Yi-Chun Tsai, Mei-Chuan Kuo, and Shang-Jyh Hwang. "Exploring the Benefit of 2-Methylbutyric Acid in Patients Undergoing Hemodialysis Using a Cardiovascular Proteomics Approach." Nutrients 11, no. 12 (December 12, 2019): 3033. http://dx.doi.org/10.3390/nu11123033.

Повний текст джерела
Анотація:
Short-chain fatty acids (SCFAs) can reduce pro-inflammatory parameters and oxidative stress, providing potential cardiovascular (CV) benefits. Although some evidence links SCFAs with host metabolic health via several biological mechanisms, the role of SCFA on CV disease in patients with kidney disease remains unclear. Herein, we investigate the association between a SCFA, 2-methylbutyric acid, and target CV proteomics to explore the potential pathophysiology of SCFA-related CV benefit in patients with kidney disease. Circulating 2-methylbutyric acid was quantified by high-performance liquid chromatography and 181 CV proteins by a proximity extension assay in 163 patients undergoing hemodialysis (HD). The associations between 2-methylbutyric acid and CV proteins were evaluated using linear regression analysis with age and gender, and multiple testing adjustment. The selected CV protein in the discovery phase was further confirmed in multivariable-adjusted models and evaluated by continuous scale association. The mean value of circulating 2-methylbutyric acid was 0.22 ± 0.02 µM, which was negatively associated with bone morphogenetic protein 6 (BMP-6) according to the false discovery rate (FDR) multiple testing adjustment method. The 2-methylbutyric acid level remained negatively associated with BMP-6 (β coefficient −1.00, 95% confidence interval −1.45 to −0.55, p < 0.001) after controlling for other CV risk factors in multivariable models. The cubic spline curve demonstrated a linear relationship. In conclusion, circulating 2-methylbutyric acid level was negatively associated with BMP-6, suggesting that this pathway maybe involved in vascular health in patients undergoing HD. However, further in vitro work is still needed to validate the translation of the mechanistic pathways.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Olin, Jeffrey W., Antonio F. Di Narzo, Valentina d’Escamard, Daniella Kadian-Dodov, Haoxiang Cheng, Adrien Georges, Annette King, et al. "A plasma proteogenomic signature for fibromuscular dysplasia." Cardiovascular Research 116, no. 1 (August 19, 2019): 63–77. http://dx.doi.org/10.1093/cvr/cvz219.

Повний текст джерела
Анотація:
Abstract Aims Fibromuscular dysplasia (FMD) is a poorly understood disease that predominantly affects women during middle-life, with features that include stenosis, aneurysm, and dissection of medium-large arteries. Recently, plasma proteomics has emerged as an important means to understand cardiovascular diseases. Our objectives were: (i) to characterize plasma proteins and determine if any exhibit differential abundance in FMD subjects vs. matched healthy controls and (ii) to leverage these protein data to conduct systems analyses to provide biologic insights on FMD, and explore if this could be developed into a blood-based FMD test. Methods and results Females with ‘multifocal’ FMD and matched healthy controls underwent clinical phenotyping, dermal biopsy, and blood draw. Using dual-capture proximity extension assay and nuclear magnetic resonance-spectroscopy, we evaluated plasma levels of 981 proteins and 31 lipid sub-classes, respectively. In a discovery cohort (Ncases = 90, Ncontrols = 100), we identified 105 proteins and 16 lipid sub-classes (predominantly triglycerides and fatty acids) with differential plasma abundance in FMD cases vs. controls. In an independent cohort (Ncases = 23, Ncontrols = 28), we successfully validated 37 plasma proteins and 10 lipid sub-classes with differential abundance. Among these, 5/37 proteins exhibited genetic control and Bayesian analyses identified 3 of these as potential upstream drivers of FMD. In a 3rd cohort (Ncases = 506, Ncontrols = 876) the genetic locus of one of these upstream disease drivers, CD2-associated protein (CD2AP), was independently validated as being associated with risk of having FMD (odds ratios = 1.36; P = 0.0003). Immune-fluorescence staining identified that CD2AP is expressed by the endothelium of medium-large arteries. Finally, machine learning trained on the discovery cohort was used to develop a test for FMD. When independently applied to the validation cohort, the test showed a c-statistic of 0.73 and sensitivity of 78.3%. Conclusion FMD exhibits a plasma proteogenomic and lipid signature that includes potential causative disease drivers, and which holds promise for developing a blood-based test for this disease.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Méndez, Lucía, Silvia Muñoz, Bernat Miralles-Pérez, Maria Rosa Nogués, Sara Ramos-Romero, Josep Lluis Torres, and Isabel Medina. "Modulation of the Liver Protein Carbonylome by the Combined Effect of Marine Omega-3 PUFAs and Grape Polyphenols Supplementation in Rats Fed an Obesogenic High Fat and High Sucrose Diet." Marine Drugs 18, no. 1 (December 30, 2019): 34. http://dx.doi.org/10.3390/md18010034.

Повний текст джерела
Анотація:
Diet-induced obesity has been linked to metabolic disorders such as cardiovascular diseases and type 2 diabetes. A factor linking diet to metabolic disorders is oxidative stress, which can damage biomolecules, especially proteins. The present study was designed to investigate the effect of marine omega-3 polyunsaturated fatty acids (PUFAs) (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) and their combination with grape seed polyphenols (GSE) on carbonyl-modified proteins from plasma and liver in Wistar Kyoto rats fed an obesogenic diet, namely high-fat and high-sucrose (HFHS) diet. A proteomics approach consisting of fluorescein 5-thiosemicarbazide (FTSC) labelling of protein carbonyls, visualization of FTSC-labelled protein on 1-DE or 2-DE gels, and protein identification by MS/MS was used for the protein oxidation assessment. Results showed the efficiency of the combination of both bioactive compounds in decreasing the total protein carbonylation induced by HFHS diet in both plasma and liver. The analysis of carbonylated protein targets, also referred to as the ‘carbonylome’, revealed an individual response of liver proteins to supplements and a modulatory effect on specific metabolic pathways and processes due to, at least in part, the control exerted by the supplements on the liver protein carbonylome. This investigation highlights the additive effect of dietary fish oils and grape seed polyphenols in modulating in vivo oxidative damage of proteins induced by the consumption of HFHS diets.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Pratt, Charlotte, and Sam Feudo. "A Portfolio Analysis of Nutritional Biomarkers in NIH- and NHLBI-funded Research, 2008–2020." Current Developments in Nutrition 6, Supplement_1 (June 2022): 390. http://dx.doi.org/10.1093/cdn/nzac054.045.

Повний текст джерела
Анотація:
Abstract Objectives Nutrition biomarkers are important in elucidating disease risks and severity, as surrogate markers of nutritional status, and provide objective measures of dietary intake. This study analyzed grants that investigated nutritional biomarkers and were funded between 2008 and 2020 by the National Heart, Lung, and Blood Institute (NHLBI) and across the National Institutes of Health (NIH). Methods Data were extracted using the NIH iSearch portfolio analysis platform to curate grant applications to the NIH and NHLBI. Keywords included nutrition or diet, followed by omics, metabolomics, lipidomics, proteomics, transcriptomics, genomics, and epigenomics. Funded and unfunded nutri-omics grants were separated and examined for keywords for total expenditures, Research, Condition, and Disease Categorization (RCDC) categories, administering Institute, fiscal year, Early-Stage Investigator eligibility, and organization. Citation and publication data stemming from each awarded grant were collated using iCite. Results The total number of NIH- and NHLBI-funded grants in nutri-omics biomarkers was 1,143 and 95, respectively from 2008–2020. Total dollar amount of NIH-funded grants in nutri-omics biomarkers increased from $15M in 2008 to $59.5M in 2019 and declined to $47M in 2020. NHLBI funded grants increased substantially during the same years from $1.8M in 2008 to $7.5M in 2020. During the 12-year period, the proportion of ESI grants among funded grants increased by about 10-fold across NIH and 2-fold for NHLBI. There was an increase in the number of NHLBI research publications (500%) and relative citation ratios (RCR) (150%). Funded grants were concentrated along the East and West coasts of the United States. Major foam tree topics from NHLBI-administered nutri-omics grants included cardiovascular disease, dietary patterns, obesity, human genome, risk factors, microbiome, TMAO (trimethyl amine oxide), and fatty acids. Conclusions The analysis indicated increased funding in nutri-omics biomarkers. However, major gaps remain in topics categorized as nutrition biomarkers in NHLBI- and NIH-funded grants. More research is needed to characterize and examine novel biomarkers in NIH-funded grants. Funding Sources Not applicable.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Lecerf, Jean-Michel. "Fatty acids and cardiovascular disease." Nutrition Reviews 67, no. 5 (May 2009): 273–83. http://dx.doi.org/10.1111/j.1753-4887.2009.00194.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Mozaffarian, Dariush, Martijn B. Katan, Alberto Ascherio, Meir J. Stampfer, and Walter C. Willett. "Trans Fatty Acids and Cardiovascular Disease." New England Journal of Medicine 354, no. 15 (April 13, 2006): 1601–13. http://dx.doi.org/10.1056/nejmra054035.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Richard, Doriane, Pedro Bausero, Charlotte Schneider, and Francesco Visioli. "Polyunsaturated fatty acids and cardiovascular disease." Cellular and Molecular Life Sciences 66, no. 20 (July 10, 2009): 3277–88. http://dx.doi.org/10.1007/s00018-009-0085-4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Salter, A. M. "Dietary fatty acids and cardiovascular disease." Animal 7 (2013): 163–71. http://dx.doi.org/10.1017/s1751731111002023.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Mozaffarian, Dariush, Martijn B. Katan, Alberto Ascherio, Meir J. Stampfer, and Walter C. Willett. "Trans Fatty Acids and Cardiovascular Disease." Obstetrical & Gynecological Survey 61, no. 8 (August 2006): 525–26. http://dx.doi.org/10.1097/01.ogx.0000228706.09374.e7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Proteomics, fatty acids, cardiovascular disease"

1

Hartweg, Janine. "Omega-3 polyunsaturated fatty acids on cardiovascular disease in type 2 diabetes." Thesis, University of Oxford, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.504428.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Cottin, Sarah. "Differential effects of fatty acids on the endothelium." Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/differential-effects-of-fatty-acids-on-the-endothelium(8655cd9b-072c-4365-928c-2ab28549ad78).html.

Повний текст джерела
Анотація:
Background: Endothelial dysfunction is a major factor in the development of atherosclerosis, thrombosis and heart disease. Evidence suggests dietary fat composition may modify cardiovascular risk, as well as surrogate markers of cardiovascular risk such as blood pressure, arterial stiffness and endothelium-dependent vasodilation. Aim: To investigate the impact of dietary fat composition on endothelial function and associated markers of vascular health. Methods: The effects of oils rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were separately investigated in a parallel-design, placebo-controlled randomised controlled trial (n=48, 6 weeks, 2.9 g/d), carried out in free-living healthy young men. Following a 2 week run-in period taking placebo capsules (olive oil), participants underwent baseline measurements of finger capillary density, endothelial progenitor cell numbers (EPC), platelet-monocyte aggregate numbers (PMA), ambulatory blood pressure (ABP), pulse wave analysis (PWA), digital volume pulse analysis (DVP), and gave blood samples for plasma lipid, glucose, insulin, nitric oxide metabolites (NOx) and isoprostanes. The same measurements were made at the study endpoint, 6 weeks. An in vitro investigation of the effects of physiologically-relevant fatty acid profiles on microvascular endothelial cell nitric oxide and prostacyclin production was also performed. Results: Neither EPA nor DHA supplementation influenced EPCs, capillary density, PMA, ABP, PWA, DVP or plasma cholesterol, triacylglycerol, glucose, insulin, NOx or isoprostanes compared to placebo. However, ambulatory night-time heart rate was increased following EPA supplementation compared to DHA. Furthermore, both EPA and DHA decreased plasma non-esterified fatty acids (NEFA) compared to placebo. The in vitro investigations suggested that the composition of circulating NEFA may differentially affect endothelial function in the microvasculature. Conclusion: Dietary EPA and DHA at relatively high doses do not improve a number of novel markers of vascular function, including microvascular function and a marker of endothelial repair in young healthy men. EPA and DHA have differing effects on heart rate during sleep, suggesting that further research is required into the possible adverse effects of higher doses of individual marine fatty acids in at-risk individuals. Further work is required to elucidate the role of physiological fatty acid profiles on endothelial function.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Livingstone, Katherine Mary. "Effect of fatty acids associated with dairy products on risk of cardiovascular disease." Thesis, University of Reading, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.606933.

Повний текст джерела
Анотація:
Cardiovascular disease (CVD) and type II diabetes are the leading causes of morbidity and mortality worldwide. The impact of diet on novel, independent predictors of CVD, such as arterial stiffness, is of great interest. Findings from the Caerphilly Prospective Study, in which 2,512 men were followed up for up to 23- years, demonstrated a positive prospective association between saturated fatty acid (SFA) intake and arterial stiffness, while poly-unsaturated fatty acid (PUFA) intake was inversely associated. Furthermore, this cohort identified that dairy product intake (excluding butter) and milk were inversely associated with prospective arterial stiffness and systolic blood pressure (SSP) respectively. As milk was found to be cardio-protective, but SFA intake was associated with greater CVD risk, a study in dairy cows was designed to lower proportions of SFA in milk fat, with the aim of improving the ability of milk and dairy product consumption to reduce CVD risk further. This study identified that feeding dairy cows high proportions of maize silage (MS), as well as supplementation with extruded linseed, compared to non-supplemented, high grass silage (GS) diets, led to significantly lower proportions of milk SFA and higher proportions of monounsaturated fatty acids (MUFA) and PUFA in milk. A high SFA, low MUFA/PUFA dairy lipid, a low SFA, high MUFA/PUFA dairy lipid, and individual dairy FA were tested in an in vitro study using healthy and type II diabetic human aortic endothelial cells (HAEC) to determine possible beneficial effects of this strategy in relation to vascular function.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Skidmore, Paula Marie Louise. "Diet and cardiovascular risk : population studies in Northern Ireland." Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342981.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wang, Zherun, and 王浙潤 王浙润. "Intake of trans fatty acid and risk of cardiovascular disease in Asian population : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206974.

Повний текст джерела
Анотація:
Background Many studies in western countries have suggested a positive association between intake of trans fatty acid (TFA) and risk of cardiovascular diseases (CVDs). In Asia, although intake of TFA was relatively low, it evidenced an increasing trend which was accompanied with an increasing prevalence of CVDs among the population. There was currently no systematic review on the relationship between intake of TFA and CVDs in Asian population. This systematic review was aimed to synthesize the association between intake of TFA and the risk of CVDs in Asian population from published literature. Methods Both English and Chinese literature published before 1st January 2014were retrieved from PubMed, Medline, Google scholaand CNKI with a combination of keywords. Studies that reported the associations between intake of TFA and CVD-related risks and those conducted among Asian population were included. The quality of eligible literature included in the review was assessed based on STROBE. Findings regarding the associations between intake of TFA and risk of CVDs were extracted and synthesized through comparing and evaluating the quality of findings across the included studies. Results Of the 378 articles retrieved from the datasets, nine studies were eligible to be included in this systematic review. The nine studies covered six Asian countries including Iran, China, Korea, Japan, Israel and India. Seven of nine studies indicated a positive association between intake of TFA and risk of CVDs while the other two reported no significant association. However, none of the included studies were interventional studies and only one was prospective cohort study. Conclusion The findings that more intake of TFA was associated with increased risk of CVDs in Asian population were consistent with that in the western population. Specific regulations to restrict the use of TFA and interventions to promote public awareness of the health effects of TFA are recommended in Asian countries. Due to limited eligible studies that covered only six Asian countries, there remains cautious to generalize the findings to other Asian countries.
published_or_final_version
Public Health
Master
Master of Public Health
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hamilton, Jennifer Sara. "Interactions of glucose and long chain fatty acids in vascular smooth muscle cells : antioxidant status and cellular function." Thesis, Queen's University Belfast, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326389.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Daher, Costantine Fouad. "Dietary lipid profiles and intestinal apolipoprotein B-48 synthesis and secretion." Thesis, University of Surrey, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.244781.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Edel, Andrea L. "Metabolism and physiological actions of milled flaxseed in humans as a function of dose, participant age and cardiovascular disease status." Springer, 2013. http://hdl.handle.net/1993/31194.

Повний текст джерела
Анотація:
Basic and clinical research documents the benefits of dietary milled flaxseed (MFX), a rich source of alpha-linolenic acid (ALA) and lignans, in the attenuation of risk factors key to regulating cardiovascular disease (CVD) progression. ALA has antihypertensive properties and the lignan metabolites, enterodiol (END) and enterolactone (ENL), have antioxidative potential. The effectiveness of these bioactives to reduce risk factors of CVD may be dependent upon their plasma concentrations. To study this, we first designed and validated a method using supported liquid extraction and gas chromatography/mass spectrometry to isolate and quantify enterolignans in plasma. Applying this technique, we examined MFX doses of 10-40 g/d administered to healthy, younger adults (18-49 years of age) for 4 weeks. Ten g/d was sufficient to significantly increase circulating ALA (1.5 fold) and enterolignans (5-31 fold). There was no significant dose-dependent response. In another investigation, younger (18-29 years of age) and older (45-69 years of age) healthy adults were studied to determine if age influenced enterolignan metabolism. CVD is associated with advanced age but older people may not be able to obtain lignan metabolites from dietary MFX. Following 4 weeks of MFX consumption, both age groups increased plasma total enterolignans (END + ENL) with no between-group differences. This suggested that older and younger adults metabolize MFX lignans equally. A final study assessed MFX bioactives in plasma of peripheral artery disease patients >40 years of age. Plasma enterolignans increased 10-50 fold and ALA 1-2 fold after only one month of MFX ingestion. Dietary MFX also attenuated total (11%) and LDL (15%) cholesterol in these patients after 1-6 months of administered MFX compared to placebo. The attenuation in cholesterol was due to the high fiber content of flaxseed, and not to ALA and enterolignans, despite their marked increase in circulation. MFX did not interfere with cholesterol-lowering medications but instead decreased cholesterol levels beyond the effects of medications alone. To conclude, dietary supplementation with MFX resulted in an increase in plasma enterolignan and ALA concentrations in healthy younger and older adults and in patients with pre-existing CVD. The cholesterol-lowering benefits of MFX were additional to cholesterol-lowering drugs and likely attributed to MFX fiber.
May 2016
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Weech, Michelle. "The substitution of dietary saturated fatty acids with monounsaturated and n-6 polyunsaturated fatty acids on measures of vascular function and risk factors of cardiovascular disease." Thesis, University of Reading, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.657609.

Повний текст джерела
Анотація:
A systematic review of the evidence indicated that vascular function, a critical early modifiable event in cardiovascular disease (CVD) development, can be modulated by dietary fat composition. Saturated fat (SF A) was deleterious, with limited evidence of benefit for monounsaturated (MUFA) or n-6 polyunsaturated fat (n-6 PUFA). Studies were difficult to compare, due in part to the varying methods of vascular function determination, and on analysis, it was confirmed that these methods were not interchangeable (except pulse wave velocity and stiffness index). It was hypothesised that substituting SFA with MUFA or n-6 PUFA would improve vascular function and traditional CVD risk markers, with differential responses dependent on endothelial nitric oxide synthase (NOS3) genotype. A large parallel, randomised, controlled intervention was conducted in adults with mild risk of CVD (n=195). Using a novel food exchange model, three 16-wk isoenergetic diets (SFA-, MUFA- and n-6 PUFA rich) were implemented in free-living individuals. Target intakes were broadly met (assessed using 4-day diet records (P <0.001) and plasma phospholipid fatty acids (P <0.001 for total SFA and MUFA» , without weight change. Replacement of SFA with MUFA or n-6 PUFA did not influence vascular function, although SFA deteriorated macro- and microvascular endothelial function (P <0.05), but improved the lipid profile (P = 0.001) and CVD risk score (P = 0.003). Replacement with MUFA attenuated the SF A-induced increase in night blood pressure (P <0.05) and reduced circulating ESelectin (P = 0.025). NOS3 genotype influenced responses to the dietary manipulation differentially in males and females. Genotype*diet interactions (P <0.05) were identified for reflection index (measuring vascular tone) and triacylglycerol in females, and non-esterified fatty acids in males. In conclusion, replacing SF A with MUF A and n- 6 PUFA significantly reduces CVD risk, although the optimal replacement appears dependent on NOS3 genotype and gender, providing an effective public health strategy for reducing cardiovascular risk in a population with mild risk of CVD.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Aung, Theingi. "The role of omega-3 fatty acids and aspirin in the prevention of cardiovascular disease in diabetes and biochemical effectiveness of omega-3 fatty acids and aspirin in the ASCEND trial." Thesis, Queen Mary, University of London, 2018. http://qmro.qmul.ac.uk/xmlui/handle/123456789/36213.

Повний текст джерела
Анотація:
Background: The role of aspirin (100 mg daily) and omega-3 fatty acids (FA) (1 g daily) for primary prevention of cardiovascular disease in diabetes is being investigated in the 2x2 factorial design ASCEND trial. To support the interpretation of the trial's efficacy findings, it is important to compare self-reported compliance by participants with measures of the biochemical effects of each intervention. The previous data on the effect of supplementation with omega-3 FA on coronary heart disease is uncertain. Methods: The ASCEND trial randomly allocated 15480 people with diabetes (94% type 2 DM) who do not already have diagnosed occlusive arterial disease to receive aspirin or placebo and to omega-3 FA or placebo. Blood and urine samples were collected by mail at baseline and after 3 years follow-up. The effectiveness of aspirin to suppress urinary thromboxane B2 (UTxB2), a marker of platelet activity, and, of omega-3 FA supplements to increase red cell membrane omega-3 index were assessed. A systematic review of previous trials of omega-3 FA was conducted to summarize the prior evidence for the effects of omega-3 FA supplements on major vascular events (MVEs). Results: Aspirin reduced UTxB2 levels by 67% (63-70%) (p < 0.0001) compared with placebo, from 3453 pg/mg (95% CI 3061-3895) at baseline to 1190 pg/mg (1100-1287) on those allocated to aspirin during the trial. During follow-up, the omega-3 index increased by 33% (95% CI 26%-39%) in those allocated omega-3 FA compared to placebo (p < 0.0001). The meta-analysis of previous studies of omega-3 FA showed no effect on MVEs (HR 0.97; [0.93-1.01]) overall or in any pre-specified sub-groups. Conclusions: Low dose aspirin and omega-3 FA are biochemically effective at reducing UTxB2 and increasing the omega-3 index, respectively. Previous trials show that supplementation with omega-3 FA had no significant effect on MVEs. The results of the ASCEND trial, assessing the effects of both aspirin and omega-3 FA on MVEs, will be available in 2018.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Proteomics, fatty acids, cardiovascular disease"

1

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

United States. Agency for Healthcare Research and Quality, ed. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md.]: Agency for Healthcare Research and Quality, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

United States. Agency for Healthcare Research and Quality, ed. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md.]: Agency for Healthcare Research and Quality, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center, and United States. Agency for Healthcare Research and Quality, eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Chenchen, Wang, Tufts-New England Medical Center. Evidence-based Practice Center, and United States. Agency for Healthcare Research and Quality, eds. Effects of omega-3 fatty acids on cardiovascular disease. [Rockville, Md: Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

United States. Agency for Healthcare Research and Quality. Effects of omega-3 fatty acids on cardiovascular disease. Rockville, Md.]: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Proteomics, fatty acids, cardiovascular disease"

1

Lapous, D., C. Loriette, J. Raulin, C. Wolfrom, and M. Gautier. "Stimulatory Action of Polyunsaturated Fatty Acids on Pyruvate Oxidation." In Cardiovascular Disease, 483–93. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5296-9_52.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Leaf, A., and J. X. Kang. "ω3 Fatty Acids and Cardiovascular Disease." In World Review of Nutrition and Dietetics, 24–37. Basel: KARGER, 1998. http://dx.doi.org/10.1159/000059667.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Leaf, A., and J. X. Kang. "Omega-3 Fatty Acids and Cardiovascular Disease." In World Review of Nutrition and Dietetics, 161–72. Basel: KARGER, 2001. http://dx.doi.org/10.1159/000059783.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Beynen, A. C. "Cholesterol-lowering action of diets rich in polyunsaturated fatty acids." In Atherosclerosis and Cardiovascular Disease, 191–97. Dordrecht: Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-009-0731-7_24.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lamers, J. M. J., L. M. A. Sassen, J. M. Hartog, and P. D. Verdouw. "Dietary N-3 Fatty Acids and Ischaemic Heart Disease." In Developments in Cardiovascular Medicine, 171–81. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1607-7_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Lamers, J. M. J., L. M. A. Sassen, J. M. Hartog, C. Guarnieri, and P. D. Verdouw. "Dietary N-3 Polyunsaturated Fatty Acids and Ischemic Heart Disease." In Developments in Cardiovascular Medicine, 237–56. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-1513-1_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Mensink, R. P., and M. B. Katan. "The effects of monounsaturated fatty acids on serum lipoprotien levels in healthy adult volunteers." In Atherosclerosis and Cardiovascular Disease, 206–13. Dordrecht: Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-009-0731-7_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

De León, Estela Guerrero, Mahabir Prashad Gupta, and Juan Antonio Morán-Pinzón. "Beneficial Effects of Omega-3 Fatty Acids on Cardiovascular Disease." In Natural Products and Cardiovascular Health, 1–46. Boca Raton : Taylor & Francis, 2018.: CRC Press, 2018. http://dx.doi.org/10.1201/9780429402180-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Guilliams, Thomas G., and Jørn Dyerberg. "Marine-Derived Omega-3 Fatty Acids and Cardiovascular Disease." In Nutritional and Integrative Strategies in Cardiovascular Medicine, 77–95. 2nd ed. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003137849-4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

McEvoy, Claire, Ian S. Young, and Jayne V. Woodside. "Fish, n-3 Polyunsaturated Fatty Acids, and Cardiovascular Disease." In Nutritional Health, 221–46. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-894-8_10.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Proteomics, fatty acids, cardiovascular disease"

1

Harris, William, and Irum Zahara. "Omega-3 and cardiovascular disease." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/rrxh5251.

Повний текст джерела
Анотація:
Despite the fact that the “omega-3 lowers risk for CVD” story is now 50 years old, controversies remain regarding the short and long-term utility of omega-3 supplementation to reduce risk for CVD. The earlier studies (published roughly before 2007) were generally favorable, however a spate of studies published since then were not nearly as clear. The one stand-out in the latter set was REDUCE-IT, which used 4 g/d of EPA ethyl esters (instead of EPA+DHA ethyl esters). In this study, the treated subjects experienced about 25% fewer CVD events than the placebo group. This resulted in FDA approval for this drug for reducing risk for CVD in specific patient populations. The next large study to report out – STRENGTH – was expected to be positive as well (3.1 g EPA+DHA as free fatty acids), but it was stopped early for “futility” (i.e., the event rates were not different between active and placebo groups). Many hypotheses have been raised to explain these wildly different outcomes, and this has engendered considerable confusion in the field. These hypotheses will be discussed in this presentation. On the other hand, observational prospective cohort studies based on measured blood omega-3 levels (not on fish intake questionnaires) have consistently shown that higher levels are associated with lower risk for CVD (and total mortality). These two different study designs (RCTs vs observational epidemiology) ask different questions. This talk will synthesize these two apparently divergent conclusions regarding the utility of omega-3 fatty acids for reducing risk for CVD.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Jackson, Kristina, and Nayomi Plaza. "Challenges in proposing omega-3 fatty acid recommendations for the public." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/fgey5940.

Повний текст джерела
Анотація:
Long-chain omega-3 fatty acids, eicosapentaenoic and docosahexaenoic acids (EPA, DHA), are important nutrients, but they do not have a Dietary Reference Intake (DRI) recommendation. This lack of recognition as essential nutrients makes it difficult to set population guidelines for EPA and DHA (like the Dietary Guidelines for Americans). Challenges in proposing EPA and DHA recommendations for the public are mainly determining which health outcomes reflect a €œdeficiency€ for EPA and DHA and defining the EPA and DHA dose recommendation for the general public and at each life stage. The modernization of the DRI process to redefine what €œpreventing deficiency€ means for each nutrient includes allowing the use of chronic health conditions as signs of deficiency, which may be the path by which EPA and DHA will receive a DRI. A circulating biomarker that links EPA and DHA intake with chronic disease risk is the Omega-3 Index, defined as the proportion of EPA and DHA of total erythrocyte fatty acids. An Omega-3 Index of 8% has been shown to be associated with lower risk of cardiovascular disease and an index of less than 4% is associated with higher risk, and these benchmarks could provide a standard to which intake recommendations could be set. There is evidence that around 50% of the US and Canadian populations are less than 4% and efforts to improve omega-3 status and intake in this population may be the most important for population health, especially for pregnant women. The EPA and DHA dose needed to reach an 8% target from 4% is higher than what can reasonably be achieved through diet (1.4-2.2 g/d; daily fish intake); however, aiming to prevent deficiency, or increase the Omega-3 Index above 4% would be more in line with current recommendations (200-300 mg/d; 2 servings of omega-3-rich fish per week).
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Kang, Jeanne, and In-Hwan Kim. "Concentration of eicosapentaenoic acid via Candida rugosa lipase-catalyzed esterification with phytosterol and fatty acid from anchovy oil." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/wyzv8794.

Повний текст джерела
Анотація:
Eicosapentaenoic acid (EPA, 20:5n3), which is one of the well-known polyunsaturated fatty acids (PUFAs), is contained abundantly in anchovy oil among marine oils. EPA, along with docosapentaenoic acid (DPA, 22:5n3) and docosahexaenoic acid (DHA, 22:6n3), provide several health benefits such as reducing the risk of cardiovascular disease, cancer, and stroke, protecting vision, and increasing immunity. In the present study, EPA was concentrated efficiently in the unesterified fatty acid when Candida rugosa lipase-catalyzed esterification with phytosterol and fatty acid from anchovy oil was carried out in a solvent system. The effects of several parameters upon the concentration of EPA were investigated including the molar ratio of the substrate, temperature, and enzyme loading. The optimum conditions of molar ratio, temperature, and enzyme loading were 3:1 (phytosterol to fatty acids), 40 °C, 10 % (based on the total weight of substrate), respectively. Under the optimum conditions, EPA content in the unesterified fatty acid increased markedly from 20 % in the initial fatty acid up to 46% after the reaction time of 6 h. DPA and DHA were also concentrated in the unesterified fatty acid with a similar tendency even though the contents of both PUFAs were much lower than EPA. Consequently, the sum of EPA, DPA, and DHA content increased from 24% in the initial fatty acid up to 65% in the unesterified fatty acid, after Candida rugosa lipase-catalyzed esterification. In addition, phytosteryl ester, which has applied into fat-based food products as a functional component, was synthesized simultaneously during the concentration of EPA via enzymatic esterification.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Kris-Etherton, Penny. "The Essentiality of a Healthy Dietary Pattern Across the Lifespan for Reducing the Global Burden of Cardiovascular Disease." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/vgsg6979.

Повний текст джерела
Анотація:
Penny Kris-Etherton PhD RD FAHA FASN FNLA CLS;Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally and in the U.S. Many risk factors, including an abnormal lipid/lipoprotein profile and high blood pressure (BP) increase CVD risk. A healthy dietary pattern decreases major CVD risk factors. Diet and lifestyle factors that affect lipids/lipoproteins include: macronutrients (i.e., saturated fat, unsaturated fat including omega-6 and omega-3 fatty acids, trans fat, carbohydrate, animal/plant protein), cholesterol, sterols/stanols, fiber, principally viscous, as well as body weight & weight loss, physical activity and meal timing, among some other emerging dietary interventions. Diet and lifestyle factors that affect BP include: a DASH Dietary Pattern, body weight, sodium & potassium, alcohol and physical activity. Collectively, implementing recommended dietary interventions can markedly decrease CVD risk. New evidence is accumulating that demonstrates the importance of controlling CVD risk factors across the lifespan even before birth (i.e., in utero). Much can be done to markedly decrease CVD morbidity and mortality as the result of healthy lifestyle practices that are implemented at any stage in life, with the greatest benefit realized when started early in life and maintained throughout the lifespan.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wei, Na, Enada Archibold, Grace Jairo, and Heather Kuiper. "Development of a method for separation of geometric isomers of alpha-linolenic acid in human plasma by silver Ion HPLC and GC-NCI-MS." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/fvyw5862.

Повний текст джерела
Анотація:
Alpha-linolenic acid (ALA), an omega-3 fatty acid essential for humans, must be supplied by diet, mainly from plants. It's a precursor of omega-3 long-chain fatty acids, eicosapentaenoic and docosahexaenoic acids which are essential for human cardiovascular health. ALA consumption may also reduce the risk of heart disease. The geometric isomers of ALA in humans are derived from consumption of industrially produced partially hydrogenated and deodorized vegetable oils. The presence of trans-isomers of ALA in humans may affect the levels of regular ALA, potentially impacting the beneficial effects of ALA. Some studies have reported geometric isomers of ALA in human milk and serum but demonstrate incomplete chromatographic separation. The objective of this work is to develop a method to separate geometric isomers of ALA in human plasma using silver ion high-performance liquid chromatography (Ag-HPLC) and detect them using gas chromatography-negative chemical ionization-mass spectrometry (GC-NCI-MS). Sample preparation involves acidic and alkaline hydrolysis of samples, followed by extraction of free fatty acids with hexane. Ag-HPLC is then employed for isomer separation, HPLC fractions containing each isomer are collected, and finally the samples are analyzed by GC-NCI-MS. Preliminary data shows all eight geometric isomers of ALA (n-3t6t9t, n-3t6t9c, n-3c6t9t, n-3t6c9t, n-3t6c9c, n-3c6t9c, n-3c6c9t, and n-3c6c9c) in plasma can be separated using this approach. Ag-HPLC separation of ALA isomers in human plasma resulted in the same elution times as the isomers in a standard mixture. The identities of the isomers were confirmed by comparing their retention times and mass-to-charge ratios with those of ALA isomer standards via GC-NCI-MS. This approach can potentially be used to investigate the distribution of ALA geometric isomers in human plasma. The full resolution of ALA geometric isomers can ensure accurate identification of these isomers in human plasma, which may aid in understanding their impact on human health.
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Proteomics, fatty acids, cardiovascular disease"

1

Balk, Ethan M., Gaelen P. Adam, Valerie Langberg, Christopher Halladay, Mei Chung, Lin Lin, Sarah Robertson, et al. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Agency for Healthcare Research and Quality, August 2016. http://dx.doi.org/10.23970/ahrqepcerta223.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Legault, Jenna. Supplemental Project to Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease. Agency for Healthcare Research and Quality (AHRQ), May 2017. http://dx.doi.org/10.23970/ahrqepcmeth3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Qi, Xue, Hechen Zhu, Ru Ya, and Hao Huang. Omega-3 polyunsaturated fatty acids supplements and cardiovascular disease outcome: A systematic review and meta-analysis on randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0027.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Proteomics, fatty acids, cardiovascular disease" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії